Board of Nath Bio-Genes (India) recommends final dividend
30 - Apr - 2025 12:00 | 33 days ago
Nath Bio-Genes (India) announced that the Board of Directors of the Company at its meeting held on 29 April 2025, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.
Nath Bio-Genes (India) consolidated net profit declines 43.51% in the March 2025 quarter
30 - Apr - 2025 12:00 | 33 days ago
Net profit of Nath Bio-Genes (India) declined 43.51% to Rs 1.48 crore in the quarter ended March 2025 as against Rs 2.62 crore during the previous quarter ended March 2024. Sales rose 20.75% to Rs 51.97 crore in the quarter ended March 2025 as against Rs 43.04 crore during the previous quarter ended March 2024.
For the full year,net profit declined 2.57% to Rs 38.60 crore in the year ended March 2025 as against Rs 39.62 crore during the previous year ended March 2024. Sales rose 9.71% to Rs 364.91 crore in the year ended March 2025 as against Rs 332.62 crore during the previous year ended March 2024.
Nath Bio-Genes (India) consolidated net profit declines 43.51% in the March 2025 quarter
30 - Apr - 2025 12:00 | 33 days ago
Net profit of Nath Bio-Genes (India) declined 43.51% to Rs 1.48 crore in the quarter ended March 2025 as against Rs 2.62 crore during the previous quarter ended March 2024. Sales rose 20.75% to Rs 51.97 crore in the quarter ended March 2025 as against Rs 43.04 crore during the previous quarter ended March 2024.
For the full year,net profit declined 2.57% to Rs 38.60 crore in the year ended March 2025 as against Rs 39.62 crore during the previous year ended March 2024. Sales rose 9.71% to Rs 364.91 crore in the year ended March 2025 as against Rs 332.62 crore during the previous year ended March 2024.
Board of Nath Bio-Genes (India) recommends final dividend
30 - Apr - 2025 12:00 | 33 days ago
Nath Bio-Genes (India) announced that the Board of Directors of the Company at its meeting held on 29 April 2025, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.
Nath Bio-Genes (India) consolidated net profit declines 43.51% in the March 2025 quarter
30 - Apr - 2025 12:00 | 33 days ago
Net profit of Nath Bio-Genes (India) declined 43.51% to Rs 1.48 crore in the quarter ended March 2025 as against Rs 2.62 crore during the previous quarter ended March 2024. Sales rose 20.75% to Rs 51.97 crore in the quarter ended March 2025 as against Rs 43.04 crore during the previous quarter ended March 2024.
For the full year,net profit declined 2.57% to Rs 38.60 crore in the year ended March 2025 as against Rs 39.62 crore during the previous year ended March 2024. Sales rose 9.71% to Rs 364.91 crore in the year ended March 2025 as against Rs 332.62 crore during the previous year ended March 2024.
Board of Nath Bio-Genes (India) recommends final dividend
30 - Apr - 2025 12:00 | 33 days ago
Nath Bio-Genes (India) announced that the Board of Directors of the Company at its meeting held on 29 April 2025, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.
Nath Bio-Genes (India) consolidated net profit declines 43.51% in the March 2025 quarter
30 - Apr - 2025 12:00 | 33 days ago
Net profit of Nath Bio-Genes (India) declined 43.51% to Rs 1.48 crore in the quarter ended March 2025 as against Rs 2.62 crore during the previous quarter ended March 2024. Sales rose 20.75% to Rs 51.97 crore in the quarter ended March 2025 as against Rs 43.04 crore during the previous quarter ended March 2024.
For the full year,net profit declined 2.57% to Rs 38.60 crore in the year ended March 2025 as against Rs 39.62 crore during the previous year ended March 2024. Sales rose 9.71% to Rs 364.91 crore in the year ended March 2025 as against Rs 332.62 crore during the previous year ended March 2024.
Nath Bio-Genes (India) consolidated net profit declines 43.51% in the March 2025 quarter
30 - Apr - 2025 12:00 | 33 days ago
Net profit of Nath Bio-Genes (India) declined 43.51% to Rs 1.48 crore in the quarter ended March 2025 as against Rs 2.62 crore during the previous quarter ended March 2024. Sales rose 20.75% to Rs 51.97 crore in the quarter ended March 2025 as against Rs 43.04 crore during the previous quarter ended March 2024.
For the full year,net profit declined 2.57% to Rs 38.60 crore in the year ended March 2025 as against Rs 39.62 crore during the previous year ended March 2024. Sales rose 9.71% to Rs 364.91 crore in the year ended March 2025 as against Rs 332.62 crore during the previous year ended March 2024.